

Ocrelizumab/tozinameran interaction

XS

Impaired vaccine response: 4 case reports

A study of 59 patients described three men and one woman, aged 33–51 years, who exhibited impaired vaccine response following concomitant administration of ocrelizumab and tozinameran [*not all routes and dosages stated*].

Four patients, who had received 1–10 infusions of ocrelizumab 300mg every 2 weeks for multiple sclerosis starting from 10 January 2019 to 1 October 2020, received tozinameran [BNT162b2 mRNA] vaccine in Italy after 97–126 days from the last day of ocrelizumab infusion. The patients had no history of COVID-19 infection. All the patients were seronegative at baseline. Seven days after the second dose of tozinameran, all the patients showed a very low humoral response (impaired vaccine response), with nearly undetectable antibody titers in two patients. It was hypothesized that the previous treatment with ocrelizumab contributed to impaired vaccine response by dampening the humoral response by targeting circulating B-cells [*outcomes not stated*].

Gallo A, et al. Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab. *Neurological Sciences* 42: 3523-3526, No. 9, Sep 2021. Available from: URL: <https://link.springer.com/journal/10072>

803600164